BackNKGen Biotech- Warrants (01/09/2028) Overview
NKGen Biotech Inc - Warrants (01/09/2028)

NKGen Biotech- Warrants (01/09/2028) Return on Equity

Latest ROE for NKGen Biotech- Warrants (01/09/2028): 46.8% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

46.80%

Return on Equity

46.80%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NKGen Biotech- Warrants (01/09/2028) (NKGNW) FAQ

NKGen Biotech- Warrants (01/09/2028)'s return on equity stands at 46.8%. That is above the sector sector average of -5.68%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NKGen Biotech- Warrants (01/09/2028) sits higher the its sector benchmark (-5.68%) with a ROE of 46.8%. That is roughly 923.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 46.8% for NKGen Biotech- Warrants (01/09/2028) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how NKGen Biotech- Warrants (01/09/2028)'s ROE evolved across reporting periods, while the comparison chart places NKGNW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.